Journals / Türkiye Parazitoloji Dergisi / 2015 / Cilt: 39 - Sayı: 1

Kronik Ürtikere Neden Olan ve Uzatılmış Albendazol Kullanımı ile Başarılı Bir Şekilde Tedavi Edilen Rekürren Toxocariasis Olgusu

Recurrent Toxocariasis Due to Chronic Urticaria and Successful Treatment with Prolonged Albendazole Therapy

Pages
83–85
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Then, recurrent disease was resolved and skin lesions were diminished after prolonged albendazole therapy

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Toxocariasis is a worldwide human helminthiasis, especially seen in temperate and tropical climate regions around the world.
📊
Key Findings & Data:Albendazole is one of the treatment choices for toxocariasis, with a currently recommended regimen of 10 mg/kg/day in two doses (400 mg twice daily) for 5 days.
💡
Conclusion & Impact:Then, recurrent disease was resolved and skin lesions were diminished after prolonged albendazole therapy
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Toxocariasis is a worldwide human helminthiasis, especially seen in temperate and tropical climate regions around the world. The diagnosis of this disease is performed on the basis of clinical symptoms and laboratory findings. Albendazole is one of the treatment choices for toxocariasis, with a currently recommended regimen of 10 mg/kg/day in two doses (400 mg twice daily) for 5 days. However, there is no precise consensus about the duration of the treatment. In this article, we report a case of toxocariasis; the patient visited our infectious disease polyclinic with complaints of long-term itching and urticarial skin lesions that were resistant to routine treatment and that recurred. Then, recurrent disease was resolved and skin lesions were diminished after prolonged albendazole therapy

Özet

Toxocariasis, dünya genelinde özellikle ılıman ve tropikal iklimin hüküm sürdüğü bölgelerde görülen bir paraziter hastalıktır. Tanı klinik ve laboratuar bulguları ile konur. Albendazol (400 mg günde iki kez) 10 mg/kg/gün 5 gün süre ile kullanımı önerilen tedavi rejimlerinden biridir. Ancak, tedavi süresi ile ilgili kesin bir konsensus mevcut değildir. Bu yazıda; rutin tedaviye dirençli ve tedaviye rağmen tekrarlayan, uzun süredir devam eden kaşıntı ve ürtikeryal cilt lezyonları ile enfeksiyon hastalıkları polikliniğine başvuran ve uzatılmış albendazol tedavisi sonucu kür sağlanan bir Toxocariasis olgusu sunulmuştur

🔖

Cite This Article

GÖRENEK, L., ÖNCÜL, O., HATİPOĞLU, M., AYDIN, E., KARAGÖZ, E., ACAR, A., TURHAN, V., SELEK, M. B. (2022). Kronik Ürtikere Neden Olan ve Uzatılmış Albendazol Kullanımı ile Başarılı Bir Şekilde Tedavi Edilen Rekürren Toxocariasis Olgusu. Türkiye Parazitoloji Dergisi, Cilt: 39 - Sayı: 1, 83–85. https://ajindex.com/articles/630232

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (3)

  1. Hayashi E, Tuda J, Imada M, Akao N, Fujita K. The high prevalence of asymptomatic Toxocara infection among schoolchildren in Manado, Indonesia. Southeast Asian J Trop Med Public Health 2005; 36: 1399-1406. Arango.C.A. Visseral Larva Migrans and the hypereosinophilia Syndrome. Southern Med J 1998; 91: 882-83. [CrossRef] Winn W, Allen S, Janda W, Koneman E, Procop G, Schreckenberger P editors. Miscellaneous Larval tissue parasite infections. Koneman's Color Atlas and Textbook of Diagnostic Microbiology. Sixth edition. Philedelphia: New Lippincott Williams and Wilkins; 2006.
  2. Smith H, Holland C, Taylor M, Magnaval JF, Schantz P, Maizels R. How Common is Human Toxocariasis? Towards Standardizing Our Knowledge. Trends Parasitol 2009; 25: 182-88. [CrossRef] Shetty AK, Aviles DH. Nephrotic syndrome associated with Toxocara canis infection. Ann Trop Paediatr 1999; 19: 297-300. [CrossRef] Kagialis-Girard S, Mialou V, Ffrench M, Dupuis-Girod S, Pages MP, Bertrand Y. Thrombocytosis and toxocariasis:report of two pediatric cases. Pediatr Blood Cancer 2005; 44: 190-92. [CrossRef] Magnaval JF, Glickman LT, Dorchies P, Morassin B. Highlights of human toxocariasis. Korean J Parasitol 2001; 39: 1-11. [CrossRef] Yoshikawa M. Duration of treatment with albendazole for hepatic toxocariasis. Nat Clin Pract Gastroenterol Hepatol 2009; 6: E1-E2. [CrossRef] Stürchler D, Schubarth P, Gualzata M, Gottstein B, Oettli A. Thiabendazole vs. albendazole in treatment of toxocariasis: a clini- cal trial. Ann Trop Med Parasitol 1989; 83: 473-78.
  3. Kim MH, Jung JW, Kwon JW, Kim TW, Kim SH, Cho SH, et al. A case of recurrent toxocariasis presenting with urticaria. Allergy Asthma Immunol Res 2010; 2: 267-70. [CrossRef]